Novel Targets for Therapeutic Intervention in Inflammatory Bowel Disease: Research Drives Clinic

Author(s): Marjorie Argollo, Silvio Danese.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 1 , 2019

[1]
Argollo M, Fiorino G, Gilardi D, et al. Biosimilars of adalimumab in inflammatory bowel disease: are we ready for that? Curr Pharm Des 2019; 25(1): 7-12.
[2]
Gonczi L, Ilias A, Kurti Z, Lakatos PL. Biosimilars in IBD: Will it benefit to patients, physicians or the health care system? Curr Pharm Des 2019; 25(1): 13-8.
[3]
D’Amico F, Roda G, Peyrin-Biroulet L, Danese S. Anti-adhesion molecules in IBD: does gut specifity really make the difference? Curr Pharm Des 2019; 25(1): 19-24.
[4]
Argollo M, Allocca M, Furfaro F, Danese S. Interleukin-23 blockers: born to be first-line biologic agents in inflammatory bowel disease? Curr Pharm Des 2019; 25(1): 25-31.
[5]
Fernández-Clotet A, Castro-Poceiro J, Panés J. JAK inhibition: the most promising agents in the IBD pipeline? Curr Pharm Des 2019; 25(1): 32-40.
[6]
Paulo Gustavo Kotze PG, Spinelli A, Lightner A. Cell-based therapy for perianal fistulising Crohn’s disease. Curr Pharm Des 2019; 25(1): 41-6.
[7]
Argollo M, Gilardi D, Roda G, Fiorino G, Peyrin-Biroulet L, Danese S. Anti-fibrotic drugs for Crohn’s disease: Ready for prime time? Curr Pharm Des 2019; 25(1): 47-56.
[8]
Yzet C, Tse SS, Kayal M, Hirten R, Colombel JF. Novel targets for therapeutic intervention in inflammatory bowel disease. What is the best way to assess the safety profile of a drug? Curr Pharm Des 2019; 25(1): 57-63.
[9]
Lindholm CR, and Siegel CA. Are we ready to include prognostic factors in inflammatory bowel disease trials? Curr Pharm Des 2019; 25(1): 64-8.
[10]
Dan Turner Particularities of IBD trials in children. Curr Pharm Des 2019; 25(1): 69-72.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 25
ISSUE: 1
Year: 2019
Page: [5 - 6]
Pages: 2
DOI: 10.2174/138161282501190514105602

Article Metrics

PDF: 22
HTML: 5
EPUB: 2
PRC: 1